Recent trends in the management of newly diagnosed multiple myeloma
1Princess Margaret Hospital, Toronto, Ontario, Canada. donna.reece@uhn.on.ca
Purpose Of Review:
Many recent trials have been undertaken that incorporate novel agents into the treatment of newly diagnosed multiple myeloma patients. This review highlights the current status of different approaches to initial therapy in the era of novel drugs.
Recent Findings:
The therapy of newly diagnosed patients with multiple myeloma is still usually based on age and eligibility for autologous stem cell transplantation (ASCT). In older patients, several randomized trials have evaluated the addition of a novel agent to oral melphalan and prednisone, while novel agents have been incorporated before, during and after ASCT in younger individuals. Newer investigational approaches that are not age-dependent include continuous myeloma suppression with dexamethasone plus an immunomodulatory derivative, or the use of multiple cycles of combination regimens followed by a treatment break or maintenance therapy. Updated information is now also available regarding the use of nonmyeloablative allogeneic transplantation. The biologic heterogeneity of myeloma is most easily measured in the clinic by fluorescence in-situ hybridization (FISH) cytogenetics, and the detection of adverse cytogenetics is beginning to influence treatment decisions.
Summary:
Clinical trials have established the superiority of regimens containing novel agents in the initial management of myeloma, although a number of questions remain about the optimal strategy.
Insights
Novel agents improve newly diagnosed multiple myeloma treatment, with strategies varying by age and transplant eligibility. Clinical trials confirm their superiority, though optimal approaches require further research.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Multiple myeloma treatment has evolved with the introduction of novel therapeutic agents.
- Current treatment strategies are often stratified by patient age and suitability for autologous stem cell transplantation (ASCT).
Purpose of the Study:
- To review the current landscape of initial therapy for newly diagnosed multiple myeloma in the context of novel drug advancements.
- To highlight evolving treatment approaches and their impact on patient management.
Main Methods:
- Review of recent clinical trials incorporating novel agents in multiple myeloma.
- Analysis of treatment strategies based on patient age, ASCT eligibility, and cytogenetic risk.
- Inclusion of investigational approaches like continuous therapy and maintenance strategies.
Main Results:
- Regimens including novel agents demonstrate superior outcomes in newly diagnosed multiple myeloma.
- Treatment protocols are adapting to incorporate novel agents before, during, and after ASCT for younger patients.
- Older patients benefit from novel agents added to standard oral melphalan and prednisone regimens.
- Age-independent strategies and the impact of cytogenetic risk (e.g., FISH) are increasingly influencing treatment decisions.
Conclusions:
- Novel agent-containing regimens are superior for initial multiple myeloma management.
- Optimal treatment strategies require further investigation to address remaining clinical questions.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...